Background-Aggressive blood pressure (BP) control has been advocated in patients with acute coronary syndrome, but few data exist in this population relative to cardiovascular outcomes.
D ata from observational studies involving more than 1 million individuals without preexisting vascular disease have indicated that deaths due to both ischemic heart disease and stroke increase progressively and linearly with blood pressure (BP). 1 Consequently, the notion that "lower is better" 2 has been popular for management of hypertension. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure states, "The relationship between BP and risk of cardiovascular events is continuous, consistent, and independent of other risk factors." 3 Subsequently, a BP of Ͻ120/80 mm Hg has been considered "optimal" 4 or "normal." 3
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However, this linear theory has been challenged for nearly 3 decades, especially for diastolic pressure. [5] [6] [7] [8] Physiologically, a J-or U-shaped curve phenomenon would be expected to exist in vital components such as BP and other biological systems, with an increased mortality exhibited at both ends of the spectrum. The linear relationship might hold true for the general population, but in patients with stable coronary artery disease, the relationship between BP and cardiovascular outcomes has been shown in some studies to follow a J-or a U-shaped curve, with higher event rates at very low and very high BP. 5,7,9 -14 However, this is controversial. The Seventh Report of the Joint National Committee states, "There is no definitive evidence of an increase in risk of aggressive treatment (a J-curve) unless the diastolic BP is lowered to Ͻ55 or 60 mm Hg by treatment." 3 In the American Heart Association scientific statement on "Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease," a target of Ͻ130/80 mm Hg has been recommended in patients at high risk of coronary artery disease and acute coronary syndromes (ACS), but it was acknowledged that there were limited data to support this recommendation. 15 We aimed to analyze what data exist for the target range of BP in patients after ACS.
Methods

Patient Population and Study Design
We analyzed patients enrolled in the PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial 16, 17 which was an international, multicenter, randomized, double-blind, 2ϫ2 factorial design trial of men or women at least 18 years old hospitalized with ACS (either myocardial infarction [MI] , with or without ST-segment elevation, or high-risk unstable angina) in the preceding 10 days who were randomly assigned to receive pravastatin 40 mg or atorvastatin 80 mg once daily and to receive gatifloxacin or placebo. The protocol required that the baseline total cholesterol level be Ͻ240 mg/dL in statin-naive patients or Ͻ200 mg/dL in patients previously given a statin. Patients were managed with standard medical and interventional treatment for ACS.
Follow-Up
Patients were followed up for 18 to 36 months (average 24 months), with visits at 30 days, 4 months, and every 4 months thereafter. At each visit, vital signs and information on clinical end points, adverse events, and concurrent medication use were collected. During each visit, BP was recorded, and blood samples were collected and analyzed at a central laboratory. BP management was at the discretion of the treating physician.
For the present analysis, average follow-up systolic and diastolic pressures were calculated for each patient by use of all postbaseline results up to the last visit before the date of primary outcome or the end of follow-up in those patients without events. The baseline value was substituted for patients with no postbaseline data. The risk of cardiovascular outcomes was then evaluated as a function of BP.
Study Outcomes
Primary and secondary outcomes measures in the present analysis were the same as for the main PROVE IT-TIMI 22 trial. 16, 17 The primary outcome was the time from randomization to the first occurrence of death due to any cause, MI, documented unstable angina requiring hospitalization, revascularization with either percutaneous coronary intervention or coronary artery bypass graft performed more than 30 days after randomization, and stroke. The secondary outcome was a composite of death due to coronary heart disease, nonfatal MI, or revascularization after 30 days. Tertiary outcomes consisted of all-cause mortality, death due to coronary heart disease, and nonfatal MI considered as separate outcomes.
Statistical Analyses
BP values were categorized in 10-mm Hg increments for association with clinical outcomes. Patient groups were compared by 1-way analysis of variance (ANOVA) or Kruskal-Wallis rank test for continuous variables and 2 test for categorical variables.
The decision to use the average on-treatment follow-up BP category was based on the following: We created separate models (unadjusted and adjusted) using baseline pressure, follow-up pressure, and average on-treatment follow-up pressures and calculated the predictive value of the models using the concordance index (C statistic). The end of follow-up (adjusted C statistic of 0.62 for systolic BP and 0.63 for diastolic BP) and average follow-up pressure variables (adjusted C statistic of 0.62 for systolic and 0.63 for diastolic BP) were higher than those for the baseline BP variables (adjusted C statistic of 0.60 for systolic and 0.60 for diastolic pressure), which suggests a higher predictive value than with the baseline BP variables. Because the average follow-up BP variable represents the effect of pressure over a period of time rather than at 1 point in time, we considered this to be more important for prediction of long-term events and used this for the rest of the analyses. However, we performed similar modeling (for events) with baseline pressure variables. We hypothesized that if a J-or U-shaped relationship was found with both baseline and average follow-up BP variables and outcomes, it was likely due to reverse causality (with low BP being a mere marker of ill health). If, however, a J-or U-shaped relationship was found with average follow-up BP but not at baseline, the BP itself was more likely to contribute to increased events at follow-up.
Univariate Cox proportional hazards analysis was performed to assess the risk of outcomes for each 10-mm Hg increment in BP. Multivariable Cox proportional hazards analysis was performed that included BP category as the major factor, with adjustment for age, sex, smoking, baseline body mass index, history of hypertension, diabetes mellitus, history of coronary artery bypass graft surgery, coronary angioplasty, angina pectoris, cerebrovascular disease, peripheral arterial disease, heart failure, arrhythmia, baseline C-reactive protein level, average follow-up low-density lipoprotein levels, and treatment effect. This was done for the whole cohort and for the 2 treatment groups separately in accordance with the intention-to-treat principle. The adjusted hazard ratio for each category of systolic or diastolic BP was calculated in reference to the systolic BP group in which the event rate was lowest (nadir BP calculated by the delta method as outlined below), for which the hazard ratio was considered as 1.
In addition, nonlinear Cox proportional hazards models were estimated with mean BP as a continuous variable and with the square of BP. Unadjusted hazard ratios were calculated on the basis of univariate Cox proportional hazards analysis that included BP and BP squared only. Adjusted hazard ratios were calculated on the basis of multivariate Cox proportional hazards analysis that included the major predictors BP and BP squared adjusted for the confounding variables listed previously. Overall BP effects were examined on the basis of a likelihood ratio test that compared a full model that included both linear and quadratic mean BP terms plus other covariates (in adjusted analysis only) and a reduced model without the linear and quadratic mean BP terms. Nadir BP was calculated on the basis of the delta method, which is equal to the coefficient of the linear term divided by Ϫ2 times the coefficient of the quadratic term. Furthermore, interactions between treatments by mean BP and BP squared were examined on the basis of the likelihood ratio test by comparison of a full model that included both linear and quadratic mean BP terms plus treatment plus other covariates (in adjusted analysis) versus a reduced model without the 2 interaction terms.
A P value of Ͻ0.05 was considered statistically significant for all tests. All analyses were performed with Stata software version 9.2 (College Station, Tex).
Results
Patients
A total of 4162 patients who had been hospitalized for an ACS within the preceding 10 days were randomized to pravastatin 40 mg or atorvastatin 80 mg per day. The main results of the trial have been discussed elsewhere. 17 Tables 1 and 2 show baseline characteristics by systolic and diastolic pressure categories, respectively. Patients with low systolic pressure were a lower-risk cohort who were more likely to be younger, male, leaner, and to have never smoked; they were less likely to have risk factors (hypertension, diabetes, prior MI, coronary artery bypass graft surgery, angioplasty, peripheral arterial disease, heart failure, stroke or transient ischemic attack, or chronic renal failure); and they had lower levels of baseline low-density lipoprotein cholesterol/high-density lipoprotein cholesterol/triglycerides but higher levels of baseline C-reactive protein than patients with high systolic pressure (Table 1) . In contrast, patients with low diastolic pressure were older and more likely to be female and hypertensive and to have prior coronary artery bypass graft surgery, heart failure, and peripheral arterial disease than patients with high diastolic pressure.
Baseline Characteristics
BP and Primary Outcome
Among the 4162 patients, 1000 (24%) reached the primary outcome. The relationship between systolic pressure and the incidence of primary outcome followed a J-or U-shaped shaped curve, with an increased event rate at low and high systolic pressures ( Figure 1A ). After adjustment for baseline covariates, treatment effect, baseline C-reactive protein, and average on-treatment low-density lipoprotein cholesterol levels, compared with the reference group (BP Ͼ130 to 140 mm Hg), the risk of primary outcome increased 4.9-fold in the group with systolic BP Յ100 mm Hg and by 1.2-fold in the group with systolic BP Ͼ160 mm Hg ( Figure 1A) . A nonlinear Cox proportional hazards model with systolic pressure on a continuous scale ( 2 ϭ49, PϽ0.0001) identified a nadir of 136 mm Hg at which the event rate was the lowest. This was true for the overall cohort ( Figure 1A ) and separately for the 2 treatment cohorts (data not shown). The J-or U-shaped relationship was more pronounced with average follow-up BP than with baseline BP variables ( Figure 1B) .
The relationship between diastolic pressure and the incidence of primary outcome also followed a J-or U-shaped curve, with increased event rates at low and high diastolic pressures ( Figure  1C ). After adjustment for baseline covariates and for treatment BMI indicates body mass index; FH, family history; CAD, coronary artery disease; MI, myocardial infarction; CABG, coronary artery bypass graft surgery; CHF, congestive heart failure; TIA, transient ischemic attack; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; CRP, C-reactive protein; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; and CCB, calcium channel blocker.
*P values are based on 1-way analysis of variance for continuous variables (ie, age, BMI, and LDL-C) and Pearson's 2 test for the remaining categorical variables. †Baseline medication usage 2 weeks before qualifying event before randomization.
effect, compared with the reference group (BP Ͼ80 to 90 mm Hg), the risk of primary outcome increased 3.7-fold in the group with diastolic BP Յ60 mm Hg and 2.1-fold in the group with diastolic BP Ͼ100 mm Hg ( Figure 1C) . A nonlinear Cox proportional hazards model with diastolic BP on a continuous scale ( 2 ϭ52, PϽ0.0001) identified a nadir of 85 mm Hg at which the event rate was the lowest ( Figure 1C ). This was true for the overall cohort ( Figure 1C ) and separately for the 2 treatment cohorts (data not shown). The J-or U-shaped relationship was more pronounced with average follow-up BP than with baseline BP variables ( Figure 1D ).
BP and Secondary Outcome
Among the 4162 patients, 856 (21%) patients reached the secondary outcome. A similar J-or U-shaped relationship with secondary outcome was found for both systolic ( 2 ϭ37, PϽ0.0001; Figure 2A ) and diastolic ( 2 ϭ47, PϽ0.0001; Figure 2C ) pressure in both the unadjusted and adjusted models, with a nadir at 137/84 mm Hg. However, as with the primary outcome, the J-or U-shaped relationship was more pronounced with average follow-up BP variables than with baseline BP variables ( Figure 2B and 2D ).
BP and Tertiary Outcomes
Among the 4162 patients, 119 (2.9%) died; 53 (1.3%) of these were cardiovascular deaths, 260 (6.2%) had a nonfatal MI, and 40 (0.96%) had a stroke. A J-or U-shaped relationship was found for both systolic ( 2 ϭ10, Pϭ0.007; Figure  3A ) and diastolic ( 2 ϭ11, Pϭ0.0007; Figure 3C ) pressure with all-cause mortality in both the unadjusted and adjusted models. The J-or U-shaped relationship was found with average follow-up BP variables but not with baseline BP variables ( Figure 3B and 3D) . A J-or U-shaped relationship with cardiovascular mortality was also found for both systolic ( 2 ϭ6, Pϭ0.041; Figure 4A ) and diastolic ( 2 ϭ14, Pϭ0.0007; Figure 4C ) pressure in both the unadjusted and adjusted models. The J-or U-shaped relationship was found with average follow-up BP variables but not with baseline BP variables ( Figure 4B and 4D) . Similarly, a J-or U-shaped relationship with nonfatal MI was found for both systolic ( 2 ϭ26, PϽ0.0001; Figure 5A ) and diastolic ( 2 ϭ24, PϽ0.0001; Figure 5C ) pressure in both the unadjusted and adjusted models, with a nadir at 134/84 mm Hg. The J-or U-shaped relationship was found with average follow-up BP variables but not with baseline BP variables ( Figure 5B and 5D ). Abbreviations as in Table 1 .
All of the above relationships were true for the overall cohort and separately for the 2 treatment cohorts (data not shown). The event rate for stroke (0.96%) was too small to derive any meaningful relationship between BP and stroke. The incidence ratio of nonfatal MI to stroke remained constant for a wide range of BPs; however, at lower diastolic pressures, the incidence of nonfatal MI was much higher than the incidence of stroke, which implies that a compromised coronary circulation resulting from low diastolic pressures could be a more important factor for MI than for stroke.
Sensitivity Analysis
To evaluate the effect of pulse pressure, we performed a sensitivity analysis that controlled for it. The results were unchanged when the analysis was repeated after controlling for pulse pressure (data not shown). We also evaluated the joint distribution of systolic and diastolic pressures in a number of ways. There was only a modest correlation between the 2 variables (rϭ0.58, 95% CIϭ0.56 to 0.60). The mean diastolic pressures for each systolic pressure category ( Figure 1A) showed no distribution of higher diastolic pres-sures for low systolic categories and vice versa; the same was true for diastolic BP categories ( Figure 1C ). In a model designed to predict whether the risk of events was higher in those with low systolic pressure or diastolic pressure or in those with both low systolic and diastolic pressures, the test for interaction was not significant, and the risk of events was comparable for all 3 categories.
Discussion
The present analysis of a high-risk post-ACS population enrolled in the PROVE IT-TIMI 22 trial showed that a J-or U-shaped relationship existed between BP and the risk of cardiovascular outcomes such that there was an exponential increase in event rates at high and low BP values. The relationship was true for both systolic and diastolic BP. The analyses identified a BP nadir of 136/85 mm Hg at which the event rate was the lowest; however, the curve was relatively flat for systolic pressures of 110 to 130 mm Hg and diastolic pressures of 70 to 90 mm Hg. A BP Ͻ110/70 mm Hg was associated with an increased risk of cardiovascular events, which suggests that a BP that is too low indentifies a subset of patients with poor prognosis. 
Shifting Paradigm of Intensive BP Management
In patients treated for hypertension, guidelines recommend a target of Յ140/90 mm Hg, with lower targets (Յ130/ 80 mm Hg) for special populations such as those with diabetes, renal impairment, or coronary artery disease. 3, 18, 19 However, the evidence to support a lower BP target is not robust. In the Action to Control Cardiovascular Risk in Diabetes BP trial, 20 there was no reduction in the rate of fatal and nonfatal major cardiovascular outcomes with intensive management (target systolic pressure Ͻ120 mm Hg) compared with a standard target of Ͻ140 mm Hg among high-risk persons with type 2 diabetes mellitus. Similarly, in a Cochrane meta-analysis of 7 randomized trials, Arguedas et al 21 showed no difference in cardiovascular morbidity and mortality with intensive BP management (target Յ135/85 mm Hg) compared with standard targets (Յ140 to 160/Յ90 to 100 mm Hg).
The results of the present analyses extend the above observation to the highest-risk cohort, those with established coronary artery disease after ACS, and suggests not only a flat curve for BP 110 to 130/70 to 90 mm Hg but also a higher risk of cardiovascular events at lower pressures. This suggests that the paradigm of "lower is better" in cardiovascular medicine is not applicable to BP control beyond a certain target.
BP and the J-Curve Phenomenon
The J-or U-shaped curve phenomenon with BP has been explored for more than 3 decades. Most of the prior studies were retrospective analyses or post hoc analyses of randomized trials of hypertensive cohorts. In patients without known coronary artery disease, the existence of a J-or U-shaped curve has not been shown consistently. Stewart 8 showed a Jor U-shaped relationship for MI and cardiovascular death with a nadir at a diastolic pressure of 100 to 109 mm Hg. The Australian National BP Trial 22 echoed these findings, with a nadir at 85 to 89 mm Hg of diastolic pressure. Conversely, an analysis of the International Prospective Primary Prevention Study in Hypertension trial failed to show a J-or U-shaped curve. 23 More recently, an analysis of the Hypertension Optimal Treatment trial showed a J-shaped curve for both systolic and diastolic pressure for cardiovascular death, with a nadir at 139/86 mm Hg, 24 similar to the nadir of 137/ 84 mm Hg shown in the present study. A meta-analysis of individual patient data from 7 randomized trials showed a Jor U-shaped curve for all-cause and cardiovascular mortality, with a nadir at 156/84 mm Hg. However, in a recent randomized trial of nondiabetic hypertensive subjects, tight control of BP (mean 132/77 mm Hg) was associated with a significant reduction in cardiovascular events compared with usual control (mean 136/79 mm Hg). 25 Of note, the above studies enrolled very few or no patients with known coronary artery disease.
The optimal BP for patients with coronary artery disease, especially post-ACS patients, is not well defined. A recent American Heart Association statement suggests a target of Ͻ130/80 mm Hg in this cohort. 15 Insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis study (CAMELOT), which enrolled patients with "normal" BP (baseline 129/78 mm Hg), appear to suggest that further BP reduction might be beneficial 26 ; however, the optimal target is less well defined. Few studies have evaluated the J-or U-shaped curve phenomenon in patients with hypertension and coronary artery disease. Cruickshank et al 5 showed a J-shaped relationship between cardiovascular death and diastolic BP, but only in patients with known coronary artery disease, with a nadir at 85 to 90 mm Hg. Similarly, data from the Framingham Heart Study also showed a J-or U-shaped relationship for cardiovascular mortality, but only in patients with prior MI. 27 In the International Verapamil-SR Trandolapril study of 22 576 patients with hypertension and coronary artery disease, a J-or U-shaped relationship was shown between BP and cardiovascular outcomes, 7 and the relationship was stronger in patients without prior angioplasty, which suggests that patients with prior angioplasty tolerated low diastolic pressures better than those without. In the recently published Ongoing Telmisartan Alone and in Combination With Ramipril Global End-Point Trial (ONTARGET) of patients with atherosclerotic disease or diabetes with organ damage, a J-or U-shaped relationship with cardiovascular mortality and MI was shown for both systolic and diastolic pressure. 28 The present data are concordant with prior studies showing a J-or U-shaped relationship; however, the present study differs from prior studies in many respects. Unlike the prior studies in hypertensive cohorts, the present study is a post hoc analysis of patients after ACS. Unlike other hypertension studies, the treatment of hypertension and the choice of medications were left to the discretion of the managing physician. The present study also showed that the degree of statin therapy did not mitigate the J-or U-shaped curve phenomenon. The J-or U-shaped relationship persisted after we controlled for baseline C-reactive protein and average on-treatment low-density lipoprotein cholesterol levels.
Pathophysiological Mechanisms for J-Curve Phenomenon
Several "pathophysiological" mechanisms have been proposed to explain the existence of a J-or U-shaped curve. The results of the present analyses can be explained by any these mechanisms either singly or in combination. It has been hypothesized that the J-or U-shaped curve may be an epiphenomenon of more severe underlying chronic illness (including cancer) or underlying severe cardiac illness (like heart failure), thereby increasing mortality. However, only 1% to 5% of patients in the present study had a history of heart failure at baseline, with a lower percentage in those with lower systolic BP. In addition, the J-or U-shaped relationship between BP (both systolic and diastolic) and outcomes persisted even after we controlled for baseline covariates. Moreover, the results are from data derived from a randomized trial in which patients with debilitating illness (for example, advanced cancer with a survival of Ͻ2 years) are excluded. In addition, if the Jor U-shaped curve were due to reverse causality (low BP variables being a mere marker of ill health), the relationship should have been seen with both baseline and average follow-up BP variables. In our analyses, the J-or U-shaped relationship was found with average on-treatment BP variables but not at baseline, which suggests that decreased BP per se might be a contributor to the increased events. However, other unmeasured indicators of poor health were not taken into consideration in the present analysis.
The J-or U-shaped curve may represent an epiphenomenon of increased arterial stiffness, and thus, a low diastolic BP might be a marker for high pulse pressure and an increase in mortality. 29 In our analyses, we noticed a J-or U-shaped curve phenomenon not just for diastolic but also for systolic BP, for which the pulse pressure theory would not be applicable.
A low diastolic BP may compromise coronary perfusion in subjects with coronary heart disease, because coronary perfusion occurs in diastole. In the present analysis, all patients were post-ACS patients, and the incidence ratio of nonfatal MI to stroke increased at low diastolic pressures, which emphasizes that at low BP, MI is more likely than stroke. This can be explained by impaired coronary perfusion and is a more likely explanation given that we observed a more pronounced J-or U-shaped curve effect with follow-up BP variables than with baseline BP variables. However, the present study does not prove a causal relationship between low pressure (either systolic or diastolic) and an increased risk of events, although the differential effect on outcomes between baseline and follow-up BP values appears to suggest that a low BP might be causally related to outcomes. 
Study Limitations
The present study was a post hoc analysis that evaluated the relationship between BP and cardiovascular events in a coronary artery disease population with tight control of cholesterol levels, and hence, the results cannot be extrapolated to other populations. We did not adjust our analyses for all possible confounders, especially those that are predictors of poor health, such as socioeconomic status, job stress, and mental health. We also did not adjust our analyses for dosage of antihypertensive agents received. Finally, therapies that reduce systolic BP usually reduce diastolic pressure as well, which makes it difficult to determine precisely whether differences in event rates observed at the lower range were caused by reduced systolic or diastolic BP or their combination.
Conclusions
In post-ACS patients, a J-or U-shaped curve association existed between BP and the risk of future cardiovascular events, with the lowest event rates in the BP range of approximately 130 to 140/80 to 90 mm Hg and a relatively flat curve for pressures of 110 to 130/70 to 90 mm Hg, which suggests that too low of a pressure (especially Ͻ110/ 70 mm Hg) may be dangerous. Thus, although our data generally support the "lower is better" approach, this only goes so far. The present findings provide support for the Seventh Report of the Joint National Committee's guideline recognition of a possible increased risk when diastolic pressures are lowered to Ͻ60 mm Hg. Our findings are consistent with a recent randomized trial 20 and a large observational study 30 in stable patients that showed no benefit of more intensive BP management (beyond standard lowering of systolic BP to Ͻ140 mg/dL) but also extend the observation to a high-risk group of post-ACS patients. 
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